5th Annual Sickle Cell Education Day Conference – May 20, 2023

Building a Better Today for a Better Tomorrow

5th Annual Conference (Virtual)

May 20, 2023 9 am - 4 pm

Discussions on:

HEAR FROM LEADING NATIONAL EXPERTS IN THEIR FIELDS

Some Featured Speakers Include...
SCD - Adrienne Scott MD

Dr. Adrienne Williams
Scott, MD

Chief – Wilmer Eye Institute. Bel Air, Johns Hopkins Medicine, Baltimore, MD

SCD - Brian Laurence DDS

Dr. Brian Laurence, DDS, Ph.D.
Howard University College of Dentistry, Washington DC
Professor

SCD - Porteus Head Shot

Dr. Matthew Porteus, MD, PhD.
Sutardja Chuk Professor of Definitive and Curative Medicine, Stanford University, Palo Alto, CA
Pediatrics – Stem Cell Transplantation

SCD - Kavanagh-Patricia

Dr. Patricia Kavanagh, MD
Boston University School of Medicine
Associate Professor of Pediatrics

**Lunch is on us if you visit all our exhibitors!**

PLATINUM SPONSOR

GOLD SPONSOR

SILVER SPONSORS

BRONZE SPONSORS

Loading...

Share this post

CONTACT US
KEEP IN TOUCH
Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top

Breaking News

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

On December 8, 2023, “The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy."